Clinical value and potential pathways of miR-183-5p in bladder cancer: A study based on miRNA-seq data and bioinformatics analysis

Abstract

Abstract. The clinicopathological value and exploration of the potential molecular mechanism of microRNA-183-5p (miR-183-5p) have been investigated in various cancers; however, to the best of the author's knowledge, no similar research has been reported for bladder cancer. In the present study, it was revealed that the expression level of miR-183-5p was notably increased in bladder cancer tissues compared with adjacent non-cancerous tissues (P=0.001) and was markedly increased in the tissue samples of papillary, pathological T stage (T0-T2) and pathological stage (I-II) compared with tissue samples of their counterparts (P=0.05), according to data from The Cancer Genome Atlas. Receiver operating characteristic analysis revealed the robust diagnostic value of miR-183-5p for distinguishing bladder cancer from non-cancerous bladder tissues (area under curve=0.948; 95% confidence interval: 0.919-0.977). Amplification and deep deletion of miR-183-5p were indicated by cBioPortal, accounting for 1% (4/412) of bladder cancer cases. Data from YM500v3 demonstrated that compared with other cancers, bladder cancer exhibited high expression levels of miR-183-5p, and miR-183-5p expression in primary solid tumors was much higher compared with solid normal tissues. A meta-analysis indicated that miR-183-5p was more highly expressed in bladder cancer samples compared with normal counterparts. A total of 88 potential target genes of miR-183-5p were identified, 13 of which were discerned as hub genes by protein-protein interaction. The epithelial-to-mesenchymal transition pathway was the most significantly enriched pathway by FunRich (P= 0.0001). In summary, miR-183-5p may participate in the tumorigenesis and development of bladder cancer via certain signaling pathways, particularly the epithelial-to-mesenchymal transition pathway. However, the exact molecular mechanism of miR-183-5p in bladder cancer must be validated by in vitro and in vivo experiments.

Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study

“…Moreover, the increased release of the tumor-suppressor let-7c in the culture medium found in the HG-compared to the LG-NMIBC cells could suggest a reduction of anti-cancer effect of let-7c in the cells, to maintain their oncogenic potential, as already observed in other tumor systems [27]. Several reports associate miRNA expression to cancer stage, also in BC [8,11,28]. In the present study we found a relevant association of increased urinary let-7c cluster levels in T1 stage disease.…”

Identification of exosomal and non‑exosomal microRNAs associated with the drug resistance of ovarian cancer

“…As expected, miR-183-5p and miR-760 have been proven to serve as proto-oncogenes in cancer. For instance, Gao et al (37) revealed that the expression level of miR-183-5p was notably increased in bladder cancer tissues compared with adjacent non-cancerous tissues, and was markedly associated with papillary subtype and early pathological stage (I–II) according to the tumor-node-metastasis classification, with a diagnostic performance of 94.8% reported following the receiver operating characteristic analysis. Furthermore, Cheng et al (38) demonstrated that overexpression of miR-183-5p significantly enhanced the cell proliferation and inhibited cell apoptosis in the breast cancer cell lines MCF-7 and MDA-MB-231.…”

miR‐205‐3p promotes proliferation and reduces apoptosis of breast cancer MCF‐7 cells and is associated with poor prognosis of breast cancer patients

“…With the environmental deterioration and other factors, a younger trend of breast cancer occurrence has been shown in recent years 20 The radical surgical resection, combined with radiotherapy and chemotherapy, marks the improvement regarding the survival time of early breast cancer patients, but its therapeutic effect is not satisfactory on advanced breast cancer patients 21 miRNA, as a kind of endogenous small noncoding RNA, plays an important role in cell differentiation, proliferation, and apoptosis through regulating the signaling pathway. Accumulative evidences indicate that a variety of miRNAs are involved in the regulation process of several tumors and play similar roles to tumor suppressor genes and oncogenes 22,23 The abnormal expressions of miR-21 and miR-205 are possibly related to the occurrence and development of breast cancer 12 Li et al 24 found that the miR-205 expression level is increased in epithelial ovarian cancer, and is closely related to the proliferation and invasion of ovarian cancer. In this study, we found that the level of miR-205-3p was significantly upregulated in breast cancer tissues, and further in vitro assay by overexpressing miR-205-3p validated its role on proliferation, invasion, and apoptosis of cancer cells, which was in line with previous findings 24 .…”

“…at the age of 45-65 years. Accumulative evidences indicate that a variety of miRNAs are involved in the regulation process of several tumors and play similar roles to tumor suppressor genes and oncogenes22,23 The abnormal expressions of miR-21 and miR-205 are possibly related to the occurrence and development of breast cancer12 Li et al 24 found that the miR-205 expression level is increased in epithelial ovarian cancer, and is closely related to the proliferation and invasion of ovarian cancer. Accumulative evidences indicate that a variety of miRNAs are involved in the regulation process of several tumors and play similar roles to tumor suppressor genes and oncogenes22,23 The abnormal expressions of miR-21 and miR-205 are possibly related to the occurrence and development of breast cancer12 Li et al 24 found that the miR-205 expression level is increased in epithelial ovarian cancer, and is closely related to the proliferation and invasion of ovarian cancer.…”